- Home
- BCAB vs ALVR Comparison
BCAB vs ALVR Comparison
Compare BCAB & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- ALVR
- Stock Information
- Founded
- BCAB 2007
- ALVR 2013
- Country
- BCAB United States
- ALVR United States
- Employees
- BCAB N/A
- ALVR N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAB Health Care
- ALVR Health Care
- Exchange
- BCAB Nasdaq
- ALVR Nasdaq
- Market Cap
- BCAB 96.2M
- ALVR 87.7M
- IPO Year
- BCAB 2020
- ALVR 2020
- Fundamental
- Price
- BCAB $2.08
- ALVR $0.94
- Analyst Decision
- BCAB Strong Buy
- ALVR Sell
- Analyst Count
- BCAB 2
- ALVR 5
- Target Price
- BCAB $6.00
- ALVR $1.00
- AVG Volume (30 Days)
- BCAB 1.6M
- ALVR 155.6K
- Earning Date
- BCAB 11-08-2024
- ALVR 11-04-2024
- Dividend Yield
- BCAB N/A
- ALVR N/A
- EPS Growth
- BCAB N/A
- ALVR N/A
- EPS
- BCAB N/A
- ALVR N/A
- Revenue
- BCAB N/A
- ALVR N/A
- Revenue This Year
- BCAB N/A
- ALVR N/A
- Revenue Next Year
- BCAB N/A
- ALVR N/A
- P/E Ratio
- BCAB N/A
- ALVR N/A
- Revenue Growth
- BCAB N/A
- ALVR N/A
- 52 Week Low
- BCAB $1.14
- ALVR $0.58
- 52 Week High
- BCAB $4.02
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- BCAB 55.80
- ALVR 69.10
- Support Level
- BCAB $1.87
- ALVR $0.74
- Resistance Level
- BCAB $2.13
- ALVR $0.91
- Average True Range (ATR)
- BCAB 0.12
- ALVR 0.06
- MACD
- BCAB 0.00
- ALVR 0.01
- Stochastic Oscillator
- BCAB 68.90
- ALVR 94.50
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.